scholarly journals Emotional distress following genetic testing for hereditary breast and ovarian cancer: A meta-analytic review.

2009 ◽  
Vol 28 (4) ◽  
pp. 510-518 ◽  
Author(s):  
Jada G. Hamilton ◽  
Marci Lobel ◽  
Anne Moyer
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Emotional Distress ◽  
Breast And Ovarian Cancer ◽  
Analytic Review

Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations

2019 ◽  
Vol 25 (4) ◽  
pp. 575-577
Author(s):  
Marie E. Wood ◽  
Judy E. Garber ◽  
Claudine Isaacs ◽  
Shahla Masood ◽  
Isabelle Bedrosian ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Breast And Ovarian Cancer

scholarly journals Oncologists' opinions on genetic testing for breast and ovarian cancer

2001 ◽  
Vol 3 (2) ◽  
pp. 120-125 ◽  
Author(s):  
Julie O Culver ◽  
Judy L Hull ◽  
Deborah F B Dunne ◽  
Wylie Burke
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Breast And Ovarian Cancer

scholarly journals Psychosocial Aspects of Familial Breast and Ovarian Cancer: Psychological Guidelines for Genetic Testing

1999 ◽  
Vol 15 (1-3) ◽  
pp. 152-153 ◽  
Author(s):  
M. Decruyenaere ◽  
G. Evers-Kiebooms ◽  
E. Claes ◽  
L. Denayer ◽  
M. Welkenhuysen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Psychosocial Aspects ◽  
Breast And Ovarian Cancer

scholarly journals Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System

Cancers ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 338 ◽  
Author(s):  
Matthew Richardson ◽  
Hae Jung Min ◽  
Quan Hong ◽  
Katie Compton ◽  
Sze Wing Mung ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Health Care ◽  
Genetic Testing ◽  
Population Based ◽  
Gene Panel ◽  
Wait Times ◽  
Genetic Counsellor ◽  
Care Providers ◽  
Cancer Genetic ◽  
Breast And Ovarian Cancer

New streamlined models for genetic counseling and genetic testing have recently been developed in response to increasing demand for cancer genetic services. To improve access and decrease wait times, we implemented an oncology clinic-based genetic testing model for breast and ovarian cancer patients in a publicly funded population-based health care setting in British Columbia, Canada. This observational study evaluated the oncology clinic-based model as compared to a traditional one-on-one approach with a genetic counsellor using a multi-gene panel testing approach. The primary objectives were to evaluate wait times and patient reported outcome measures between the oncology clinic-based and traditional genetic counselling models. Secondary objectives were to describe oncologist and genetic counsellor acceptability and experience. Wait times from referral to return of genetic testing results were assessed for 400 patients with breast and/or ovarian cancer undergoing genetic testing for hereditary breast and ovarian cancer from June 2015 to August 2017. Patient wait times from referral to return of results were significantly shorter with the oncology clinic-based model as compared to the traditional model (403 vs. 191 days; p < 0.001). A subset of 148 patients (traditional n = 99; oncology clinic-based n = 49) completed study surveys to assess uncertainty, distress, and patient experience. Responses were similar between both models. Healthcare providers survey responses indicated they believed the oncology clinic-based model was acceptable and a positive experience. Oncology clinic-based genetic testing using a multi-gene panel approach and post-test counselling with a genetic counsellor significantly reduced wait times and is acceptable for patients and health care providers.

scholarly journals SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)

2019 ◽  
Vol 22 (2) ◽  
pp. 193-200 ◽  
Author(s):  
S. González-Santiago ◽  
◽  
T. Ramón y Cajal ◽  
E. Aguirre ◽  
J. E. Alés-Martínez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Genetic Diagnosis ◽  
Treatment Strategies ◽  
Parp Inhibitors ◽  
Breast And Ovarian Cancer ◽  
Brca Mutations ◽  
Clinical Criteria ◽  
Therapeutic Implications ◽  
New Genes

AbstractMutations in BRCA1 and BRCA2 high penetrance genes account for most hereditary breast and ovarian cancer, although other new high-moderate penetrance genes included in multigene panels have increased the genetic diagnosis of hereditary breast and ovarian cancer families by 50%. Multigene cancer panels provide new challenges related to increased frequency of variants of uncertain significance, new gene-specific cancer risk assessments, and clinical recommendations for carriers of mutations of new genes. Although clinical criteria for genetic testing continue to be largely based on personal and family history with around a 10% detection rate, broader criteria are being applied with a lower threshold for detecting mutations when there are therapeutic implications for patients with breast or ovarian cancer. In this regard, new models of genetic counselling and testing are being implemented following the registration of PARP inhibitors for individuals who display BRCA mutations. Massive sequencing techniques in tumor tissue is also driving a paradigm shift in genetic testing and potential identification of germline mutations. In this paper, we review the current clinical criteria for genetic testing, as well as surveillance recommendations in healthy carriers, risk reduction surgical options, and new treatment strategies in breast cancer gene-mutated carriers.

The impact of the medicare benefits schedule on genetic testing in hereditary breast and ovarian cancer: An audit of test request practices in Western Australia

Pathology ◽  
2018 ◽  
Vol 50 ◽  
pp. S100
Author(s):  
Sarah L. Nickerson ◽  
Jamie-Lee Ricciardi ◽  
Ratna Dubey ◽  
Deborah Norman ◽  
Natasha Buzzacott ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Genetic Testing ◽  
Western Australia ◽  
Breast And Ovarian Cancer ◽  
The Impact ◽  
Test Request
Sign in / Sign up

Export Citation Format

Share Document